Efficacy and Safety of Valsartan and Nebivolol/Valsartan in Hypertensive Patients With LVH
Status:
Completed
Trial end date:
2018-01-25
Target enrollment:
Participant gender:
Summary
To assess the efficacy of Left Ventricular Hypertrophy (LVH) reduction and 24-hour blood
pressure control of Valsartan 80mg or Nebivolol/Valsartan 5/80mg once daily as replacement
therapy for currently treated or untreated hypertensive patients with LVH not at BP goal.
Phase:
Phase 4
Details
Lead Sponsor:
Trinity Hypertension & Metabolic Research Institute